Compare WOLF & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOLF | EYPT |
|---|---|---|
| Founded | 1987 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 838.3M | 967.4M |
| IPO Year | 1993 | 2005 |
| Metric | WOLF | EYPT |
|---|---|---|
| Price | $21.34 | $13.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $10.50 | ★ $29.60 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $759,700,000.00 | $42,339,000.00 |
| Revenue This Year | $16.42 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.05 | $3.91 |
| 52 Week High | $36.60 | $14.96 |
| Indicator | WOLF | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 54.51 |
| Support Level | $16.47 | $13.43 |
| Resistance Level | $23.12 | $14.96 |
| Average True Range (ATR) | 1.69 | 0.87 |
| MACD | 0.45 | 0.14 |
| Stochastic Oscillator | 75.46 | 65.57 |
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.